Roche's Q4 results and innovative advancements make it a strong pick. Its late-stage pipeline supports our belief that there ...
Roche's drug portfolio shows promise, but mixed indicators reveal uncertainties. Check out the risks, opportunities, and ...
NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...
The weight-loss drug market is heating up, with Swiss company Roche making a bold move by acquiring Carmot Therapeutics for up to $3.1 billion in 2023. This investment is aimed at accelerating its ...